Raymond James raised the firm’s price target on Tenet Healthcare to $85 from $72 and keeps a Strong Buy rating on the shares. Tenet’s Q1 results beat expectations across the board driven by broad strength in volumes, particularly at USPI as SS surgery cases increased 7.9% y/y, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare price target raised to $84 from $73 at RBC Capital
- Tenet Healthcare price target raised to $105 from $70 at Barclays
- Tenet Healthcare sees FY23 adjusted EPS $4.92-$6.09
- Tenet Healthcare reports Q1 adjusted EPS $1.42 vs. $1.90 last year
- HCA Healthcare price target raised to $323 from $294 at BofA